MENU
+Compare
REGN
Stock ticker: NASDAQ
AS OF
Aug 29 closing price
Price
$580.70
Change
+$1.09 (+0.19%)
Capitalization
61.43B

REGN Regeneron Pharmaceuticals Forecast, Technical & Fundamental Analysis

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation... Show more

Industry: #Biotechnology
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for REGN with price predictions
Aug 29, 2025

Momentum Indicator for REGN turns positive, indicating new upward trend

REGN saw its Momentum Indicator move above the 0 level on August 13, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for REGN just turned positive on August 15, 2025. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 253 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for REGN moved out of overbought territory on August 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

REGN broke above its upper Bollinger Band on August 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.052) is normal, around the industry mean (19.615). P/E Ratio (14.607) is within average values for comparable stocks, (52.235). Projected Growth (PEG Ratio) (1.187) is also within normal values, averaging (2.663). Dividend Yield (0.005) settles around the average of (0.043) among similar stocks. P/S Ratio (4.583) is also within normal values, averaging (303.992).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. REGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

REGN is expected to report earnings to fall 24.83% to $9.69 per share on October 30

Regeneron Pharmaceuticals REGN Stock Earnings Reports
Q3'25
Est.
$9.69
Q2'25
Beat
by $4.39
Q1'25
Missed
by $0.26
Q4'24
Beat
by $0.80
Q3'24
Beat
by $0.74
The last earnings report on August 01 showed earnings per share of $12.89, beating the estimate of $8.50. With 574.38K shares outstanding, the current market capitalization sits at 61.43B.
A.I.Advisor
published Dividends

REGN is expected to pay dividends on September 03, 2025

Regeneron Pharmaceuticals REGN Stock Dividends
A dividend of $0.88 per share will be paid with a record date of September 03, 2025, and an ex-dividend date of August 18, 2025. The last dividend of $0.88 was paid on June 06. Read more...
A.I. Advisor
published General Information

General Information

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
777 Old Saw Mill River Road
Phone
+1 914 847-7000
Employees
13450
Web
https://www.regeneron.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UCRD21.58N/A
N/A
VictoryShares Corporate Bond ETF
KNOV27.02N/A
N/A
Innovator U.S. Small Cp Pwr Buf ETF -Nov
ZALT31.54-0.03
-0.10%
Innovator U.S. Equity 10 Buffr ETF - Qt
CGCP22.58-0.12
-0.53%
Capital Group Core Plus Income ETF
SFYX15.81-0.09
-0.58%
SoFi Next 500 ETF

REGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ROIV. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+0.19%
ROIV - REGN
41%
Loosely correlated
-0.08%
IDYA - REGN
40%
Loosely correlated
-1.52%
ACLX - REGN
39%
Loosely correlated
-1.22%
IOVA - REGN
38%
Loosely correlated
N/A
TECH - REGN
38%
Loosely correlated
+0.55%
More